Sarah Thornton, MD
Ophthalmology · Philadelphia, PANPI 1316393994
Payments from drug & device makers
What this record shows
Amgen accounts for 67.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $1,892 and has fallen 91.6% since, to $158 in 2025.
Across 60 payments — averaging $57.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Alcon$183
- AstraZeneca$182
- Merz Pharmaceuticals, LLC$177
- Mallinckrodt Hospital Products Inc.$172
- Bristol Myers Squibb$126
- plus $291 from 8 others
What the payments were for
- Speaking & faculty fees$1,40040%
- Food & beverage$2,07360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 37 | $2,342 |
| Alcon | 2 | $183 |
| AstraZeneca | 3 | $182 |
| Merz Pharmaceuticals, LLC | 3 | $177 |
| Mallinckrodt Hospital Products Inc. | 4 | $172 |
| Bristol Myers Squibb | 1 | $126 |
| Sanofi | 1 | $99 |
| Biogen | 3 | $67 |
| UCB, Inc. | 1 | $32 |
| Argenx US, Inc. | 1 | $25 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $23 |
| Eyepoint US, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$1,533
- Constellation$130
- ZEPOSIA$126
- XEOMIN$125
- ACTHAR$119
How this compares
$3,473 in reported general payments places this provider in the 70th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pyridostigmine Bromide | 63 | $4,555 |
| Acetazolamide ErAcetazolamide | 18 | $1,715 |
| Prednisone | 118 | $1,375 |
| Latanoprost | 33 | $440 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $356 |
| Famotidine | 33 | $317 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Philadelphia
- Julia HallerPhiladelphia$1.5M
- Beeran MeghparaPhiladelphia$496K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
- Anton KolomeyerPhiladelphia$355K
- Durga BorkarPhiladelphia$150K
- Rachel NiknamPhiladelphia$142K
- Joseph MarkoffPhiladelphia$130K
- Leslie KatzPhiladelphia$105K
- Zeba SyedPhiladelphia$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.